Search

Diane J Levitan

from Tenafly, NJ
Age ~63
Get Report
Also known as:
Diane N
Phone and address:
1 Lyle Ave, Tenafly, NJ 07670
(201) 871-0722
Related to:
Ann Marie Redman, 78Jamie L Allen, 40Rebecca Hutchinson, 29Leonard M LevitanKatherine D LevitanJoanne T Hutchinson, 97Thomas Hutchinson, 64Nathaniel Hutchinson, 33Noname HutchinsonG Hutchinson
Connected to:
Benjamin M Levitan, 40Jerry Levitan, 91Krista R Levitan, 60Max Levitan, 34Miriam Levitan, 79Ruven Levitan, 98Shana P Levitan, 39Jeffrey G Levitas, 77Jennifer M Levitas, 57Justin Levitas, 66

Diane Levitan Phones & Addresses

  • 1 Lyle Ave, Tenafly, NJ 07670 (201) 871-0722
  • 53 Newcomb Rd, Tenafly, NJ 07670 (201) 871-0722
  • New Hyde Park, NY
  • Princeton, NJ
  • 1 S Lyle Ave, Tenafly, NJ 07670 (201) 247-2343

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: Associate degree or higher

Emails

r***[email protected]

Professional Records

Medicine Doctors

Diane Levitan Photo 1

Diane E. Levitan

View page
Specialties:
Internal Medicine
Work:
Multicare Inpatient Services
315 Martin Luther King Jr Way, Tacoma, WA 98405
(253) 403-1291 (phone)
Education:
Medical School
University of California, San Diego School of Medicine
Graduated: 2000
Procedures:
Electrocardiogram (EKG or ECG)
Conditions:
Acute Myocardial Infarction (AMI)
Acute Renal Failure
Anemia
Atrial Fibrillation and Atrial Flutter
Bipolar Disorder
Languages:
English
Spanish
Description:
Dr. Levitan graduated from the University of California, San Diego School of Medicine in 2000. She works in Tacoma, WA and specializes in Internal Medicine. Dr. Levitan is affiliated with Tacoma General Hospital.

Resumes

Resumes

Diane Levitan Photo 2

Founder, Director At Helping Promote Animal Welfare (Helping Paw), Inc

View page
Location:
Greater New York City Area
Industry:
Veterinary
Diane Levitan Photo 3

Diane Levitan

View page
Location:
Greater New York City Area
Industry:
Veterinary
Diane Levitan Photo 4

Diane Levitan

View page
Diane Levitan Photo 5

Diane Levitan

View page
Diane Levitan Photo 6

Diane Levitan

View page
Diane Levitan Photo 7

Diane Levitan

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Diane Levitan
Owner
Bright Heart Veterinary Referral and Emergency Center
Veterinary Services
609 Cantiague Rock Rd, Westbury, NY 11590
Diane Levitan
Owner
Center Specialized Vet Care
Veterinary Svcs
609 Cantiague Rock Rd #5, Westbury, NY 11590
(516) 420-0000
Diane M. Levitan
Vmd
Peace Love Pets Veterinar
Ret Misc Merchandise
6229 Jericho Tpke, Commack, NY 11725
(631) 499-5098
Diane Levitan
Owner
The Center for Specialized Veterinary Care
Veterinary Services
609 Cantiague Rock Rd, Westbury, NY 11590
(516) 420-0000

Publications

Us Patents

Sel-12 Related Methods

View page
US Patent:
6958320, Oct 25, 2005
Filed:
Mar 26, 2004
Appl. No.:
10/811199
Inventors:
Iva Greenwald - New York NY, US
Diane Levitan - Tenafly NJ, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K038/00
C12N015/00
US Classification:
514 2, 530350, 800 21
Abstract:
This invention provides an isolated nucleic acid molecule encoding a SEL-12. This invention further provides an isolated nucleic acid molecule which encodes a mutated SEL-12. This invention also provides an isolated nucleic acid molecule which encodes a mutated SEL-12, wherein the mutated SEL-12 contains at least one of the following: position 115 is a leucine, position 132 is an arginine, position 215 is a glutamic acid, position 229 is a valine, position 254 is a valine, position 255 is a valine, position 371 is a valine, position 387 is a tyrosine, position 104 is an isoleucine or position 204 is a valine. This invention further provides different uses of these nucleic acid molecules. This invention also provides different sel-12 mutants and transgenic animals which carry wild-type or mutated sel-12.

Il-8 Biomarker For Monitoring Cancer Treatment With Certain Erk Inhibitors

View page
US Patent:
8586543, Nov 19, 2013
Filed:
Aug 17, 2009
Appl. No.:
13/059796
Inventors:
Ahmed A. Samatar - West Windsor NJ, US
Brian Long - Scotch Plains NJ, US
Priya Dayananth - Summit NJ, US
Diane Levitan - Tenafly NJ, US
Marsha Smith - Princeton NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 38/00
A61K 45/00
US Classification:
514 192, 514 193, 514 194, 514 195, 514 196, 424 852
Abstract:
The present application includes methods for using IL-8 as a biomarker for, e. g. , tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.

Functional Assays For Cholesterol Absorption Inhibitors

View page
US Patent:
20060161994, Jul 20, 2006
Filed:
Dec 12, 2005
Appl. No.:
11/301094
Inventors:
Diane Levitan - Tenafly NJ, US
Marsha Smith - Princeton NJ, US
International Classification:
A01K 67/033
US Classification:
800003000, 800013000
Abstract:
The present invention relates to functional assays performed in worms that are useful for the identification of NPC1L1 inhibitors. Compositions useful for the performance of such assays are also provided.

Panel Of Biomarkers For Prediction Of Fti Efficacy

View page
US Patent:
20080090242, Apr 17, 2008
Filed:
Sep 28, 2007
Appl. No.:
11/864163
Inventors:
Diane Levitan - Tenafly NJ, US
Andrea Basso - New City NY, US
Marvin Bayne - Westfield NJ, US
Walter Bishop - Pompton Plains NJ, US
Paul Kirschmeier - Basking Ridge NJ, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention provides, inter alia, methods for selecting a patient with cancer for treatment with a farnesyl protein transferase inhibitor as well as methods for treating said patient.

Identification Of Sel-12 And Uses Thereof

View page
US Patent:
6787641, Sep 7, 2004
Filed:
Oct 6, 2000
Appl. No.:
09/043944
Inventors:
Iva Greenwald - New York NY
Diane Levitan - Tenafly NJ
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C07H 2102
US Classification:
536 231, 435 691, 4353201, 4352523, 435325, 435640, 435455, 435471, 530350, 514 2, 514 44, 424 936, 424 937
Abstract:
This invention provides an isolated nucleic acid molecule encoding a SEL-12. This invention further provides an isolated nucleic acid molecule which encodes a mutated SEL-12. This invention also provides an isolated nucleic acid molecule which encodes a mutated SEL-12, wherein the mutated SEL-12 contains at least one of the following: position 115 is a leucine, position 132 is an arginine, position 215 is a glutamic acid, position 229 is a valine, position 254 is a valine, position 255 is a valine, position 371 is a valine, position 387 is a tyrosine, position 104 is an isoleucine or position 204 is a valine, This invention further provides different uses of these nucleic acid molecules. This invention also provides different sel-12 mutants and transgenic animals which carry wild-type or mutated sel-12.

Dosing Regimen Of Anti-Lag3 Antibody And Combination Therapy With Anti-Pd-1 Antibody For Treating Cancer

View page
US Patent:
20210347889, Nov 11, 2021
Filed:
Nov 4, 2019
Appl. No.:
17/289810
Inventors:
- Rahway NJ, US
Elliot K. Chartash - Basking Ridge NJ, US
Kenneth Emancipator - Bernardsville NJ, US
Rosario Garrido - Wayne NJ, US
Jane Anne Healy - Hoboken NJ, US
Jonathan W. Juco - Ridgewood NJ, US
Diane Levitan - Tenafly NJ, US
Qing Zhao - Jersey City NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.
Control profile
Diane J Levitan from Tenafly, NJ, age ~63 Get Report